Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides.

[1]  I. Melero,et al.  Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors , 2020, Science Translational Medicine.

[2]  A. Jimeno,et al.  Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors , 2020, Journal for ImmunoTherapy of Cancer.

[3]  T. de Baère,et al.  Intratumoral Immunotherapy: From Trial Design to Clinical Practice , 2020, Clinical Cancer Research.

[4]  A. Sood,et al.  Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer , 2020, Molecular Cancer Therapeutics.

[5]  Zhe-Sheng Chen,et al.  Antimicrobial Peptide Reverses ABCB1-Mediated Chemotherapeutic Drug Resistance , 2020, Frontiers in Pharmacology.

[6]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[7]  Kun Gao,et al.  Inhibitory effects of Bombyx mori antimicrobial peptide cecropins on esophageal cancer cells. , 2020, European journal of pharmacology.

[8]  L. Galluzzi,et al.  Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy , 2020, Nature Immunology.

[9]  P. Lyu,et al.  Antimicrobial Peptide TP4 Targets Mitochondrial Adenine Nucleotide Translocator 2 , 2020, Marine drugs.

[10]  Andrew L. Ferguson,et al.  The value of antimicrobial peptides in the age of resistance. , 2020, The Lancet. Infectious diseases.

[11]  Joseph Cursons,et al.  The cancer–natural killer cell immunity cycle , 2020, Nature Reviews Cancer.

[12]  C. de la Fuente-Nunez,et al.  The wasp venom antimicrobial peptide polybia‐CP and its synthetic derivatives display antiplasmodial and anticancer properties , 2020, Bioengineering & translational medicine.

[13]  Xinping Xi,et al.  Novel Frog Skin-Derived Peptide Dermaseptin-PP for Lung Cancer Treatment: In vitro/vivo Evaluation and Anti-tumor Mechanisms Study , 2020, Frontiers in Chemistry.

[14]  P. Kim,et al.  Cathelicidin-Related Antimicrobial Peptide Regulates CD73 Expression in Mouse Th17 Cells via p38 , 2020, Cells.

[15]  Ricardo Fierro-Medina,et al.  Peptides Derived from (RRWQWRMKKLG)2-K-Ahx Induce Selective Cellular Death in Breast Cancer Cell Lines through Apoptotic Pathway , 2020, International journal of molecular sciences.

[16]  F. Buonaguro,et al.  Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities , 2020, Molecules.

[17]  Yung-Hyun Choi,et al.  A Novel Peptide Oligomer of Bacitracin Induces M1 Macrophage Polarization by Facilitating Ca2+ Influx , 2020, Nutrients.

[18]  Hsiao-Mei Kuo,et al.  TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment , 2020, Cancer medicine.

[19]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[20]  yang-xin fu,et al.  Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling , 2020, Nature Immunology.

[21]  A. Melcher,et al.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy , 2020, Nature Reviews Cancer.

[22]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[23]  N. Birkbak,et al.  Cancer Genome Evolutionary Trajectories in Metastasis. , 2020, Cancer cell.

[24]  L. Zitvogel,et al.  Trial watch: STING agonists in cancer therapy , 2020, Oncoimmunology.

[25]  L. Galluzzi,et al.  PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models , 2020, Oncoimmunology.

[26]  L. Zitvogel,et al.  Trial watch: TLR3 agonists in cancer therapy , 2020, Oncoimmunology.

[27]  L. Galluzzi,et al.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment , 2019, Nature Immunology.

[28]  Simran Preet,et al.  Augmented therapeutic efficacy of 5-fluorouracil in conjunction with lantibiotic nisin against skin cancer. , 2019, Biochemical and biophysical research communications.

[29]  I. Melero,et al.  Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. , 2019, Cancer cell.

[30]  G. Hutter,et al.  Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade , 2019, Science Translational Medicine.

[31]  R. Weissleder,et al.  LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects , 2019, Cell stress.

[32]  L. Zitvogel,et al.  Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies , 2019, Nature Reviews Clinical Oncology.

[33]  Tianxin Yang,et al.  The antimicrobial peptide PFR induces necroptosis mediated by ER stress and elevated cytoplasmic calcium and mitochondrial ROS levels: cooperation with Ara-C to act against acute myeloid leukemia , 2019, Signal Transduction and Targeted Therapy.

[34]  Angela E. Leek,et al.  A clonal expression biomarker associates with lung cancer mortality , 2019, Nature Medicine.

[35]  L. Galluzzi,et al.  Pharmacological modulation of nucleic acid sensors — therapeutic potential and persisting obstacles , 2019, Nature Reviews Drug Discovery.

[36]  L. Galluzzi,et al.  Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients , 2019, Oncoimmunology.

[37]  Daniel J. Freeman,et al.  Optimizing oncolytic virotherapy in cancer treatment , 2019, Nature Reviews Drug Discovery.

[38]  J. Luke,et al.  STING pathway agonism as a cancer therapeutic , 2019, Immunological reviews.

[39]  H. K. Haugland,et al.  Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report , 2019, Journal of Medical Case Reports.

[40]  B. Sveinbjørnsson,et al.  The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma , 2019, Molecular therapy oncolytics.

[41]  J. Wolchok,et al.  Rational design of anti-GITR-based combination immunotherapy , 2019, Nature Medicine.

[42]  L. Zitvogel,et al.  Tumor lysis with LTX-401 creates anticancer immunity , 2019, Oncoimmunology.

[43]  Prahlad T. Ram,et al.  GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition , 2019, Molecular Cancer Therapeutics.

[44]  M. Merad,et al.  Host tissue determinants of tumour immunity , 2019, Nature Reviews Cancer.

[45]  Jyh-Yih Chen,et al.  Antimicrobial Peptide TP4 Induces ROS-Mediated Necrosis by Triggering Mitochondrial Dysfunction in Wild-Type and Mutant p53 Glioblastoma Cells , 2019, Cancers.

[46]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[47]  H. Koon,et al.  Cathelicidin Suppresses Colon Cancer Metastasis via a P2RX7-Dependent Mechanism , 2019, Molecular therapy oncolytics.

[48]  D. Voelker,et al.  Interaction of two antitumor peptides with membrane lipids – Influence of phosphatidylserine and cholesterol on specificity for melanoma cells , 2019, PloS one.

[49]  P. Newton,et al.  Cellular interactions constrain tumor growth , 2019, Proceedings of the National Academy of Sciences.

[50]  Mengyu Wang,et al.  Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model , 2019, Breast Cancer Research.

[51]  P. Campbell,et al.  Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions , 2019, Nature Medicine.

[52]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[53]  C. Ting,et al.  Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells , 2018, Marine drugs.

[54]  Shuang-quan Zhang,et al.  N-myristoylation of Antimicrobial Peptide CM4 Enhances Its Anticancer Activity by Interacting With Cell Membrane and Targeting Mitochondria in Breast Cancer Cells , 2018, Front. Pharmacol..

[55]  R. Marchetto,et al.  Biophysical characterization and antitumor activity of synthetic Pantinin peptides from scorpion's venom. , 2018, Biochimica et biophysica acta. Biomembranes.

[56]  J. J. Eksteen,et al.  Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals , 2018, Cell Death & Disease.

[57]  O. Kepp,et al.  Recruitment of LC3 to damaged Golgi apparatus , 2018, Cell Death & Differentiation.

[58]  P. Ascierto,et al.  Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[60]  Marco Mina,et al.  Pan-cancer inference of intra-tumor heterogeneity reveals associations with different forms of genomic instability , 2018, PLoS genetics.

[61]  G. Kroemer,et al.  The anticancer peptide RT53 induces immunogenic cell death , 2018, PloS one.

[62]  Rongqian Wu,et al.  MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells. , 2018, The international journal of biochemistry & cell biology.

[63]  H. Kwok,et al.  Triggering of cancer cell cycle arrest by a novel scorpion venom‐derived peptide—Gonearrestide , 2018, Journal of cellular and molecular medicine.

[64]  M. Ingersoll,et al.  Mechanisms of BCG immunotherapy and its outlook for bladder cancer , 2018, Nature Reviews Urology.

[65]  F. A. Oliveira,et al.  Pro-necrotic Activity of Cationic Mastoparan Peptides in Human Glioblastoma Multiforme Cells Via Membranolytic Action , 2018, Molecular Neurobiology.

[66]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[67]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[68]  C. Swanton,et al.  Determinants and clinical implications of chromosomal instability in cancer , 2018, Nature Reviews Clinical Oncology.

[69]  Shi-Ying Huang,et al.  MSP-4, an Antimicrobial Peptide, Induces Apoptosis via Activation of Extrinsic Fas/FasL- and Intrinsic Mitochondria-Mediated Pathways in One Osteosarcoma Cell Line , 2018, Marine drugs.

[70]  R. Houot,et al.  Intratumoral immunotherapy: using the tumor as the remedy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  Joel s. Brown,et al.  Classifying the evolutionary and ecological features of neoplasms , 2017, Nature Reviews Cancer.

[72]  S. S. Kanwar,et al.  Phosphatidylserine: A cancer cell targeting biomarker. , 2017, Seminars in cancer biology.

[73]  M. Amiche,et al.  Studies of the antitumor mechanism of action of dermaseptin B2, a multifunctional cationic antimicrobial peptide, reveal a partial implication of cell surface glycosaminoglycans , 2017, PloS one.

[74]  F. T. Lay,et al.  Tumor cell membrane-targeting cationic antimicrobial peptides: novel insights into mechanisms of action and therapeutic prospects , 2017, Cellular and Molecular Life Sciences.

[75]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[76]  Hui Zhao,et al.  The development of activatable lytic peptides for targeting triple negative breast cancer , 2017, Cell Death Discovery.

[77]  Benjamin J. Raphael,et al.  The evolutionary history of 2,658 cancers , 2017, Nature.

[78]  Mengyu Wang,et al.  Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model , 2017, Oncoimmunology.

[79]  B. Sveinbjørnsson,et al.  LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment. , 2017, Future medicinal chemistry.

[80]  Hanlee P. Ji,et al.  Genomic Instability in Cancer: Teetering on the Limit of Tolerance. , 2017, Cancer research.

[81]  Xiaoping Liu,et al.  Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma. , 2017, Cancer research.

[82]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[83]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[84]  Ü. Langel,et al.  Cell-penetrating peptides with intracellular organelle targeting , 2017, Expert opinion on drug delivery.

[85]  I. Poon,et al.  The plant defensin NaD1 induces tumor cell death via a non-apoptotic, membranolytic process , 2017, Cell Death Discovery.

[86]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[87]  David J. Barry,et al.  APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. , 2017, Cancer discovery.

[88]  Robert E W Hancock,et al.  Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. , 2016, Biochimica et biophysica acta.

[89]  L. Zitvogel,et al.  The oncolytic compound LTX-401 targets the Golgi apparatus , 2016, Cell Death and Differentiation.

[90]  Francine E. Garrett-Bakelman,et al.  Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia , 2016, Nature Medicine.

[91]  Junli Jia,et al.  Amphipathicity Determines Different Cytotoxic Mechanisms of Lysine- or Arginine-Rich Cationic Hydrophobic Peptides in Cancer Cells. , 2016, Journal of medicinal chemistry.

[92]  S. Ponnazhagan,et al.  Prostate cancer‐derived cathelicidin‐related antimicrobial peptide facilitates macrophage differentiation and polarization of immature myeloid progenitors to protumorigenic macrophages , 2016, The Prostate.

[93]  M. Vetizou,et al.  The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade , 2016, Cell Death and Differentiation.

[94]  J. Mirjolet,et al.  Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. , 2016, Journal of medicinal chemistry.

[95]  L. Zitvogel,et al.  The oncolytic peptide LTX-315 triggers immunogenic cell death , 2016, Cell Death and Disease.

[96]  B. Sveinbjørnsson,et al.  The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma , 2016, PloS one.

[97]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[98]  W. Hsu,et al.  In Vitro and in Vivo Anticancer Activity of Pardaxin against Proliferation and Growth of Oral Squamous Cell Carcinoma , 2015, Marine drugs.

[99]  M. Hinds,et al.  Human β-defensin 3 contains an oncolytic motif that binds PI(4,5)P2 to mediate tumour cell permeabilisation , 2015, Oncotarget.

[100]  Xia Li,et al.  APD3: the antimicrobial peptide database as a tool for research and education , 2015, Nucleic Acids Res..

[101]  L. Zitvogel,et al.  The oncolytic peptide LTX-315 triggers necrotic cell death , 2015, Cell cycle.

[102]  J. García,et al.  A Tetrameric Peptide Derived from Bovine Lactoferricin Exhibits Specific Cytotoxic Effects against Oral Squamous-Cell Carcinoma Cell Lines , 2015, BioMed research international.

[103]  B. Rinner,et al.  Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine. , 2015, Biochimica et biophysica acta.

[104]  B. Sveinbjørnsson,et al.  The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells , 2015, Oncotarget.

[105]  G. Dubyak,et al.  Human β Defensin-3 Increases CD86 Expression on Monocytes by Activating the ATP-Gated Channel P2X7 , 2015, The Journal of Immunology.

[106]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[107]  L. Zitvogel,et al.  The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization , 2015, Oncotarget.

[108]  T. Lin,et al.  Anti-proliferative effect on a colon adenocarcinoma cell line exerted by a membrane disrupting antimicrobial peptide KL15 , 2015, Cancer biology & therapy.

[109]  E. Isogai,et al.  The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimics are Potential Anticancer Drugs , 2015, Front. Oncol..

[110]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[111]  R. Tewari,et al.  Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis—a possible adjunct therapy , 2015, Tumor Biology.

[112]  L. Xia,et al.  CecropinXJ inhibits the proliferation of human gastric cancer BGC823 cells and induces cell death in vitro and in vivo. , 2015, International journal of oncology.

[113]  Igor L. Medintz,et al.  Peptides for specifically targeting nanoparticles to cellular organelles: quo vadis? , 2015, Accounts of chemical research.

[114]  Christopher G. Adda,et al.  The Tomato Defensin TPP3 Binds Phosphatidylinositol (4,5)-Bisphosphate via a Conserved Dimeric Cationic Grip Conformation To Mediate Cell Lysis , 2015, Molecular and Cellular Biology.

[115]  M. Krstic-Demonacos,et al.  Antimicrobial peptide FF/CAP18 induces apoptotic cell death in HCT116 colon cancer cells via changes in the metabolic profile , 2015, International journal of oncology.

[116]  Matthew E. Ritchie,et al.  Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production , 2014, Cell.

[117]  H. Koon,et al.  Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts , 2014, Clinical and experimental gastroenterology.

[118]  B. Rinner,et al.  Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine , 2014, BioMetals.

[119]  R. Bjerkvig,et al.  Identification of a novel lytic peptide for the treatment of solid tumours , 2014, Genes & cancer.

[120]  Marilyn A. Anderson,et al.  Phosphoinositide-mediated oligomerization of a defensin induces cell lysis , 2014, eLife.

[121]  Chandra Sekhar Ravuri,et al.  Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 , 2014, Cancer Immunology, Immunotherapy.

[122]  M. Borad,et al.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[123]  Hui Wang,et al.  The cathelicidin-BF Lys16 mutant Cbf-K16 selectively inhibits non-small cell lung cancer proliferation in vitro. , 2013, Oncology reports.

[124]  J. Talmadge,et al.  History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.

[125]  H. Kohrt,et al.  Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity , 2013, Clinical Cancer Research.

[126]  Hui Wang,et al.  BF-30 selectively inhibits melanoma cell proliferation via cytoplasmic membrane permeabilization and DNA-binding in vitro and in B16F10-bearing mice. , 2013, European journal of pharmacology.

[127]  M. Pešić,et al.  The elimination of P-glycoprotein over-expressing cancer cells by antimicrobial cationic peptide NK-2: the unique way of multi-drug resistance modulation. , 2013, Experimental cell research.

[128]  Jun Yu,et al.  Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. , 2012, Cancer research.

[129]  M. Gilliet,et al.  Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. , 2012, Blood.

[130]  S. Sieg,et al.  Membrane damage and repair in primary monocytes exposed to human β‐defensin‐3 , 2012, Journal of leukocyte biology.

[131]  Ana Salomé Veiga,et al.  Anticancer peptide SVS-1: efficacy precedes membrane neutralization. , 2012, Biochemistry.

[132]  V. Čeřovský,et al.  Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells , 2012, Peptides.

[133]  H. Vogel,et al.  Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity* , 2011, The Journal of Biological Chemistry.

[134]  D. Hoskin,et al.  Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts , 2011, Breast Cancer Research.

[135]  J. Ling,et al.  Antimicrobial and DNA-binding activities of the peptide fragments of human lactoferrin and histatin 5 against Streptococcus mutans. , 2011, Archives of oral biology.

[136]  M. V. von Duering,et al.  Oncolytic designer host defense peptide suppresses growth of human liposarcoma , 2011, International journal of cancer.

[137]  R. Hancock,et al.  The Human Cathelicidin, LL-37, Induces Granzyme-mediated Apoptosis in Regulatory T Cells , 2011, Journal of immunotherapy.

[138]  F. Jacobsen,et al.  Suppression of Soft Tissue Sarcoma Growth by a Host Defense-Like Lytic Peptide , 2011, PloS one.

[139]  Ø. Rekdal,et al.  Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells , 2011, BMC Cancer.

[140]  A. Amon,et al.  Identification of Aneuploidy-Selective Antiproliferation Compounds , 2011, Cell.

[141]  R. Hancock,et al.  The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in cytotoxic T lymphocytes. , 2011, Experimental cell research.

[142]  Jing-jing Song,et al.  A novel analog of antimicrobial peptide Polybia-MPI, with thioamide bond substitution, exhibits increased therapeutic efficacy against cancer and diminished toxicity in mice , 2010, Peptides.

[143]  Shuang-quan Zhang,et al.  A cationic amphiphilic peptide ABP-CM4 exhibits selective cytotoxicity against leukemia cells , 2010, Peptides.

[144]  M. Puertollano,et al.  The antimicrobial peptide cecropin A induces caspase-independent cell death in human promyelocytic leukemia cells , 2010, Peptides.

[145]  M. Yarmush,et al.  Lytic peptide-mediated sensitization of TRAIL-resistant prostate cancer cells to death receptor agonists. , 2010, Cancer letters.

[146]  Santosh K. Ghosh,et al.  An Antimicrobial Peptide Regulates Tumor-Associated Macrophage Trafficking via the Chemokine Receptor CCR2, a Model for Tumorigenesis , 2010, PloS one.

[147]  B. Sveinbjørnsson,et al.  Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide , 2010, Cancer Immunology, Immunotherapy.

[148]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[149]  R. Medema,et al.  Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells , 2009, Proceedings of the National Academy of Sciences.

[150]  Xia Zhao,et al.  Intratumoral Expression of Mature Human Neutrophil Peptide-1 Mediates Antitumor Immunity in Mice , 2009, Clinical Cancer Research.

[151]  Jyh-Yih Chen,et al.  A fish antimicrobial peptide, tilapia hepcidin TH2-3, shows potent antitumor activity against human fibrosarcoma cells , 2009, Peptides.

[152]  M. Gilliet,et al.  Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 , 2009, The Journal of experimental medicine.

[153]  R. Hancock,et al.  The Human Host Defense Peptide LL-37 Induces Apoptosis in a Calpain- and Apoptosis-Inducing Factor–Dependent Manner Involving Bax Activity , 2009, Molecular Cancer Research.

[154]  Y. Shai,et al.  Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. , 2009, Cancer research.

[155]  Jyh-Yih Chen,et al.  Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells , 2009, Peptides.

[156]  C. Chuang,et al.  Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. , 2008, Human gene therapy.

[157]  S. C. Kim,et al.  Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. , 2008, Cancer letters.

[158]  H. Vaudry,et al.  Characterization of antimicrobial peptides from the skin secretions of the Malaysian frogs, Odorrana hosii and Hylarana picturata (Anura:Ranidae). , 2008, Toxicon : official journal of the International Society on Toxinology.

[159]  H. Naderi-manesh,et al.  Brevinin-2R1 semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway , 2008, Journal of cellular and molecular medicine.

[160]  Xia Zhao,et al.  Human α-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice , 2008, Molecular Cancer Therapeutics.

[161]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[162]  I. Mellman,et al.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide , 2007, Nature.

[163]  B. Sveinbjørnsson,et al.  The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo , 2006, International journal of cancer.

[164]  Friedrich Paulsen,et al.  Antitumor activity of the antimicrobial peptide magainin II against bladder cancer cell lines. , 2006, European urology.

[165]  Vyacheslav Kalchenko,et al.  Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. , 2006, Cancer research.

[166]  F. Yarovinsky,et al.  Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant1 , 2005, The Journal of Immunology.

[167]  David M. Conrad,et al.  Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines , 2005, Molecular Cancer Therapeutics.

[168]  Hiroshi Isogai,et al.  C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. , 2004, Cancer letters.

[169]  Y. Shai,et al.  Suppression of Human Prostate Tumor Growth in Mice by a Cytolytic d-, l-Amino Acid Peptide , 2004, Cancer Research.

[170]  B. Haug,et al.  Enhanced antitumour activity of 15‐residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N‐terminal modifications , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[171]  Takuji Tanaka,et al.  An evaluation of the integration of non-traditional learning tools into a community based breast and cervical cancer education program: The witness project of Buffalo , 2003, BMC Cancer.

[172]  J. Svendsen,et al.  Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[173]  Paolo Bernardi,et al.  BMAP-28, an Antibiotic Peptide of Innate Immunity, Induces Cell Death through Opening of the Mitochondrial Permeability Transition Pore , 2002, Molecular and Cellular Biology.

[174]  H. Ljunggren,et al.  CD8+ T Cells Rapidly Acquire NK1.1 and NK Cell-Associated Molecules Upon Stimulation In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[175]  J. Larrick,et al.  Complementary DNA sequence of rabbit CAP18--a unique lipopolysaccharide binding protein. , 1991, Biochemical and biophysical research communications.

[176]  C. Bucana,et al.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.

[177]  T. Ganz,et al.  In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. , 1986, Blood.

[178]  T. Ganz,et al.  DEFENSINS: NATURAL PEPTIDE ANTIBIOTICS IN HUMAN NEUTROPHILS , 1986 .

[179]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[180]  N. Sharon,et al.  Mechanism of lysozyme action. , 1969, Science.

[181]  J. Oram,et al.  Inhibition of bacteria by lactoferrin and other iron-chelating agents. , 1968, Biochimica et biophysica acta.

[182]  H. I. Zeya,et al.  Antibacterial and Enzymic Basic Proteins from Leukocyte Lysosomes: Separation and Identification , 1963, Science.

[183]  A. Fleming,et al.  Observations on a Bacteriolytic Substance (?Lysozyme?) Found in Secretions and Tissues. , 1922 .

[184]  H. Puthalakath,et al.  Bcl-2 family proteins, beyond the veil. , 2020, International review of cell and molecular biology.

[185]  Ton N Schumacher,et al.  Cancer Neoantigens. , 2019, Annual review of immunology.

[186]  M. Vicent,et al.  Molecular platforms for targeted drug delivery. , 2019, International review of cell and molecular biology.

[187]  A. Garg,et al.  Type I interferons and dendritic cells in cancer immunotherapy. , 2019, International review of cell and molecular biology.

[188]  J. Banchereau,et al.  Interplay between dendritic cells and cancer cells. , 2019, International review of cell and molecular biology.

[189]  Fiorella Kotsias,et al.  Antigen processing and presentation. , 2019, International review of cell and molecular biology.

[190]  A. Lewies,et al.  The antimicrobial peptide nisin Z induces selective toxicity and apoptotic cell death in cultured melanoma cells. , 2018, Biochimie.

[191]  Wangwei,et al.  Gene Therapy with Beta-Defensin 2 Induces Antitumor Immunity and Enhances Local Antitumor Effects , 2014 .

[192]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.

[193]  C. Ting,et al.  Supplementary Materials and Methods Antibodies Tunel Staining Quantitative Real-time Pcr , 2022 .